Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Eli Lilly and Company    LLY

ELI LILLY AND COMPANY

(LLY)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
10/19/2020 10/20/2020 10/21/2020 10/22/2020 10/23/2020 Date
142.8(c) 143.59(c) 141.31(c) 141.65(c) 142.38(c) Last
3 158 872 2 188 844 1 983 653 3 057 821 2 410 163 Volume
-2.27% +0.55% -1.59% +0.24% +0.52% Change
More quotes
Financials (USD)
Sales 2020 23 794 M - -
Net income 2020 6 198 M - -
Net Debt 2020 11 489 M - -
P/E ratio 2020 21,6x
Yield 2020 2,10%
Sales 2021 25 968 M - -
Net income 2021 7 329 M - -
Net Debt 2021 8 478 M - -
P/E ratio 2021 18,0x
Yield 2021 2,29%
Capitalization 129 B 129 B -
EV / Sales 2020 5,91x
EV / Sales 2021 5,30x
Nbr of Employees 33 625
Free-Float 99,8%
More Financials
Company
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment develops, manufactures and markets products for both... 
Sector
Pharmaceuticals
Calendar
10/27Earnings Release
More about the company
Notations Surperformance© of Eli Lilly and Company
Trading Rating : Investor Rating :
More Ratings
All news about ELI LILLY AND COMPANY
10/22INVESTOR ALERT : Kaplan Fox Investigates Eli Lilly For Potential Securities Frau..
PR
10/22ELI LILLY AND COMPANY : quaterly earnings release
10/21Lilly hires external adviser for COVID-19 drug plant problems
RE
10/21REGENERON PHARMACEUTICALS : Lilly hires external adviser for COVID-19 drug plant..
RE
10/21Eli Lilly Says 1 Manufacturing Plant Underwent FDA General Surveillance Inspe..
RE
10/20SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investor..
PR
10/20THE LAW OFFICES OF FRANK R. CRUZ : Continues Its Investigation of Eli Lilly and ..
BU
10/20INVESTOR ALERT : Law Offices of Howard G. Smith Continues Investigation of Eli L..
BU
10/20ELI LILLY AND COMPANY : - Lilly Declares Fourth-Quarter 2020 Dividend
AQ
10/19GLANCY PRONGAY & MURRAY LLP : a Leading Securities Fraud Law Firm, Continues Inv..
BU
10/19ELI LILLY AND : Lilly Declares Fourth-Quarter 2020 Dividend
PR
10/19WHO says expects to hear more soon on paused COVID-19 antibody trial
RE
10/19ELI LILLY : Health Canada Approves Taltz for Non-Radiographic Axial Spondyloarth..
DJ
10/18SHANGHAI JUNSHI BIOSCIENCES : May Benefit From Covid-19 Neutralising Antibody
DJ
10/16ELI LILLY AND COMPANY : - Lilly Announces Agreement to Acquire Disarm Therapeuti..
AQ
More news
News in other languages on ELI LILLY AND COMPANY
10/22ELI LILLY AND COMPANY : Veröffentlichung des Quartalsergebnisses
10/22ELI LILLY AND COMPANY : publication des résultats trimestriels
10/14STOCK MARKET PARIS : Paris, fébrile, perd 0,31% à la mi-journée
10/14STOCK MARKET PARIS : Paris attentiste face aux incertitudes
10/14FRANKFURT STOCK EXCHANGE : La Bourse de Francfort se maintient au-dessus des 13...
More news
Stock Trading Strategies
ELI LILLY AND COMPANY - 10/16
The underlying trend is in force again
BUY
More Stock Trading Analysis
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 167,11 $
Last Close Price 142,38 $
Spread / Highest target 40,5%
Spread / Average Target 17,4%
Spread / Lowest Target -15,7%
EPS Revisions
Managers
NameTitle
David A. Ricks Chairman, President & Chief Executive Officer
Joshua L. Smiley Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Aarti S. Shah Chief Information & Digital Officer, Senior VP
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND COMPANY7.78%128 402
JOHNSON & JOHNSON-0.54%381 970
ROCHE HOLDING AG-5.33%280 343
PFIZER INC.-4.47%207 994
MERCK & CO., INC.-12.91%200 341
NOVARTIS AG-16.62%186 175